Skip to content

SCREENER CHART SD50 CALENDAR NEWS

...

Longeveron Inc. (LGVN) Stock · SELL · CRISIS | LOPJLB

Longeveron Inc. (LGVN)

Healthcare · Biotechnology · NASDAQ · US

$2.48+4.64%Close

SELLCRISIS · day 17

LGVN▼ SELL

$2.48+4.64%

Overview FinancialsFin EarningsEarn Analyst & RatingsAnalyst News Holders & ETFsHold Options

Key stats

Short interest · FINRA settlement 2026-09-30

Market cap: $49M
Beta: -0.26
P/E (TTM): -0.23

Short % float: 0.66%
Days to cover: 1.0
SI change: -50.0%

1W: -3.88%
1M: -62.65%

vs SPY 1W: -5.04%
vs SPY 1M: -65.64%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary…

Employees: 38
Headquarters: US
Founded: 2021
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 19.9M
Float: 81.7%

longeveron.com ↗

Key executives

Stephen H. Willard — Chief Executive Officer

Lisa Locklear — Chief Financial Officer, Executive Vice President & Treasurer

Paul T. Lehr — General Counsel & Secretary

SEC filings

EDGAR · CIK 17214840 · LGVN

All filings
10-K
10-Q
8-K
Form 4

Analyst consensus

Buy

Bullish375.0%

Neutral125.0%

Bearish00.0%

L $10.00Avg $10.00H $10.00

Target$10.00+303.23%

Last$2.48

Company news

globenewswire.com · 10d ago

Longeveron to Participate in Three Longevity/Aging Investment Conferences

reuters.com · 24d ago

Longeveron explores strategic options after therapy fails mid-stage trial for infant heart condition

globenewswire.com · 24d ago

Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

globenewswire.com · 37d ago

Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference

globenewswire.com · 47d ago

Longeveron Announces 1-for-10 Reverse Stock Split

globenewswire.com · 52d ago

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

seekingalpha.com · 59d ago

Longeveron Inc. (LGVN) Q2 2026 Earnings Call Transcript

globenewswire.com · 59d ago

Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update

globenewswire.com · 61d ago

Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition

globenewswire.com · 68d ago

Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026

globenewswire.com · 79d ago

Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors

globenewswire.com · 90d ago

Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer's Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer's Disease

Market news & ticker search · RSS for LGVN

LOPJLB

Independent quant research on U.S. equities & ETFs. Not personalized advice.

Product

Screener Chart Compare SD50 Thesis News Calendar

Desk

Market Heatmap Market Hours FOMC Desk Treasury Rates Congress Trades Prediction Markets

Research

How It Works Methodology Track Record Editorial Blog Changelog

Ledgers

Bull Spreads Cash-Secured Puts Covered Calls Long Puts Long Calls

Screeners

CEF Screener REIT Screener BDC Screener Preferred Screener Dividend Screener ETF Screener Crypto Screener S&P 500 Screener

Company

Pricing About Contact

Agents

GitHub·Research Chat·MCPENT·Developers

© 2026 LOPJLB Research. All rights reserved.

@lopjlb contact@lopjlb.com

RANGE

LOPJLB.COM

OHLC🔒EMALEVELS🔒STOP🔒FLIP🔒52WSIGNALS🔒BUY🔒SELL🔒EXH🔒EXH ZONE